CALL FOR PAPERS Cell Signaling: Proteins, Pathways and Mechanisms Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts

American Journal of Physiology - Cell Physiology

Volumn 309, Issue 3, 2015, Pages C139-C147

  Martin, Sean ^a   Lin, Huey ^a   Ejimadu, Chukwuemeka ^a   Lee, Techung ^a  

^a University at Buffalo SUNY   (United States)

Author keywords

Fibrocalcification; Heart failure; SFRP2; TNAP

Indexed keywords

ALKALINE PHOSPHATASE; CYCLOHEXIMIDE; PHOSPHATE; RECOMBINANT PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 2; TISSUE NONSPECIFIC ALKALINE PHOSPHATASE; TOLLOID METALLOPROTEINASE; TUNICAMYCIN; UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE 2, MOUSE; MEMBRANE PROTEIN; SFRP2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIFICATION; CARDIOMYOPATHY; CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; ENZYME ACTIVATION; HEART FAILURE; HEART FIBROBLAST; MALE; MOLECULAR CLONING; MYOCARDIAL FIBROCALCIFICATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; FIBROBLAST; HAMSTER; HEART MUSCLE CELL; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC ANIMAL;

CRICETINAE; MUS;

ALKALINE PHOSPHATASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELLS, CULTURED; CRICETINAE; FIBROBLASTS; HEK293 CELLS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MYOCYTES, CARDIAC;

EID: 84938528056     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00009.2015     Document Type: Article

References (59)

1. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, Horn A, Kireva T, Beyer C, Zwerina J, Schneider H, Sadowski A, Riener MO, MacDougald OA, Distler O, Schett G, Distler JH. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun 3: 735, 2012.
2. Aras D, Topaloglu S, Demirkan B, Deveci B, Ozeke O, Korkmaz S. Porcelain heart: A case of massive myocardial calcification. Int J Cardiovasc Imaging 22: 123–126, 2006.
3. Askevold ET, Aukrust P, Nymo SH, Lunde IG, Kaasboll OJ, Aakhus S, Florholmen G, Ohm IK, Strand ME, Attramadal H, Fiane A, Dahl CP, Finsen AV, Vinge LE, Christensen G, Yndestad A, Gullestad L, Latini R, Masson S, Tavazzi L, Ueland T. The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure. J Intern Med 275: 621–630, 2014.
4. Barnard DC, Pape L, Missri J, Dalen JE. Massive myocardial calcification and normal coronary arteries. Tex Heart Inst J 12: 363–365, 1985.
5. Baudry A, Bitard J, Mouillet-Richard S, Locker M, Poliard A, Launay JM, Kellermann O. Serotonergic 5-HT(2B) receptor controls tissuenonspecific alkaline phosphatase activity in osteoblasts via eicosanoids and phosphatidylinositol-specific phospholipase C. J Biol Chem 285: 26066–26073, 2010.
6. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 121: 737–746, 2008.
7. Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 317: 807–810, 2007.
8. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor runx-2 by akt signaling. J Biol Chem; 283: 15319–15327, 2008.
9. Capelli A, Lusuardi M, Cerutti CG, Donner CF. Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial disorders. Am J Respir Crit Care Med 155: 249–253, 1997.
10. Caudarella R, Vescini F, Buffa A, Francucci CM. Hyperphosphatemia: effects on bone metabolism and cardiovascular risk. J Endocrinol Invest 30: 29–34, 2007.
11. Caverzasio J, Manen D. Essential role of Wnt3a-mediated activation of mitogen-activated protein kinase p38 for the stimulation of alkaline phosphatase activity and matrix mineralization in C3H10T1/2 mesenchymal cells. Endocrinology 148: 5323–5330, 2007.
12. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 162: 1495–1502, 2003.
13. Clark-Greuel JN, Connolly JM, Sorichillo E, Narula NR, Rapoport HS, Mohler ER 3rd, Gorman JH 3rd, Gorman RC, Levy RJ. Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Ann Thorac Surg 83: 946–953, 2007.
14. Demer LL, Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol 34: 715–723, 2014.
15. Dobaczewski M, Frangogiannis NG. Chemokines and cardiac fibrosis. Front Biosci 1: 391–405, 2009.
16. Fatherazi S, Matsa-Dunn D, Foster BL, Rutherford RB, Somerman MJ, Presland RB. Phosphate regulates osteopontin gene transcription. J Dent Res 88: 39–44, 2009.
17. Fedde KN, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS, Waymire K, Narisawa S, Millan JL, MacGregor GR, Whyte MP. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 14: 2015–2026, 1999.
18. Gacheru SN, Trackman PC, Shah MA, O’Gara CY, Spacciapoli P, Greenaway FT, Kagan HM. Structural and catalytic properties of copper in lysyl oxidase. J Biol Chem 265: 19022–19027, 1990.
19. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 75: 890–897, 2009.
20. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 96: 717–722, 2005.
21. Griffin M, Casadio R, Bergamini CM. Transglutaminases: Nature’s biological glues. Biochem J 368: 377–396, 2002.
22. Halling Linder C, Narisawa S, Millan JL, Magnusson P. Glycosylation differences contribute to distinct catalytic properties among bone alkaline phosphatase isoforms. Bone 45: 987–993, 2009.
23. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 20: 765–776, 2009.
24. Kalenik JL, Chen D, Bradley ME, Chen SJ, Lee TC. Yeast two-hybrid cloning of a novel zinc finger protein that interacts with the multifunctional transcription factor YY 1. Nucleic Acids Res 25: 843–849, 1997.
25. Kobayashi K, Luo M, Zhang Y, Wilkes DC, Ge G, Grieskamp T, Yamada C, Liu TC, Huang G, Basson CT, Kispert A, Greenspan DS, Sato TN. Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol 11: 46–55, 2009.
26. Komekado H, Yamamoto H, Chiba T, Kikuchi A. Glycosylation and palmitoylation of Wnt-3a are coupled to produce an active form of Wnt-3a. Genes Cells 12: 521–534, 2007.
27. Kress E, Rezza A, Nadjar J, Samarut J, Plateroti M. The frizzledrelated sFRP2 gene is a target of thyroid hormone receptor alpha1 and activates beta-catenin signaling in mouse intestine. J Biol Chem 284: 1234–1241, 2009.
28. Kurayoshi M, Yamamoto H, Izumi S, Kikuchi A. Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochem J 402: 515–523, 2007.
29. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106: 1675–1680, 2010.
30. Lin H, McGrath J, Wang P, Lee T. Cellular toxicity induced by SRF-mediated transcriptional squelching. Toxicol Sci 96: 83–91, 2007.
31. Lin H, Shabbir A, Molnar M, Yang J, Marion S, Canty JM Jr, Lee T. Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells. J Cell Physiol 216: 458–468, 2008.
32. Liu X, Tan M, Gong D, Han L, Lu F, Huang S, Xu Z. Characteristics of pericardial interstitial cells and their implications in pericardial fibrocalcification. J Mol Cell Cardiol 53: 780–789, 2012.
33. Lopez-Posadas R, Gonzalez R, Ballester I, Martinez-Moya P, Romero- Calvo I, Suarez MD, Zarzuelo A, Martinez-Augustin O, Sanchez de Medina F. Tissue-nonspecific alkaline phosphatase is activated in enterocytes by oxidative stress via changes in glycosylation. Inflamm Bowel Dis 17: 543–556, 2011.
34. Lopez B, Gonzalez A, Lindner D, Westermann D, Ravassa S, Beaumont J, Gallego I, Zudaire A, Brugnolaro C, Querejeta R, Larman M, Tschope C, Diez J. Osteopontin-mediated myocardial fibrosis in heart failure: A role for lysyl oxidase? Cardiovasc Res 99: 111–120, 2013.
35. Lynch P, Lee T, Fallavollita JA, Canty JM Jr, Suzuki G. Intracoronary administration of AdvFGF-5 (fibroblast growth factor-5) ameliorates left ventricular dysfunction and prevents myocyte loss in swine with developing collaterals and ischemic cardiomyopathy. Circulation 116: I71–I76, 2007.
36. Mastri M, Shah Z, McLaughlin T, Greene CJ, Baum L, Suzuki G, Lee T. Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol 303: C1021–C1033, 2012.
37. Mastri M, Shah Z, Wang W, Hsieh K, Wooldridge B, Suzuki G, Lee T. Secreted Frizzled-related protein 2 as a target in antifibrotic intervention. Am J Physiol Cell Physiol 306: C531–C539, 2014.
38. Masuelli L, Bei R, Sacchetti P, Scappaticci I, Francalanci P, Albonici L, Coletti A, Palumbo C, Minieri M, Fiaccavento R, Carotenuto F, Fantini C, Carosella L, Modesti A, Di Nardo P. Beta-catenin accumulates in intercalated disks of hypertrophic cardiomyopathic hearts. Cardiovasc Res 60: 376–387, 2003.
39. Millan JL. The role of phosphatases in the initiation of skeletal mineralization. Calcif Tissue Int 93: 299–306, 2013.
40. Missihoun C, Zisa D, Shabbir A, Lin H, Lee T. Myocardial oxidative stress, osteogenic phenotype, and energy metabolism are differentially involved in the initiation and early progression of delta-sarcoglycan-null cardiomyopathy. Mol Cell Biochem 321: 45–52, 2008.
41. Nathan E, Tzahor E. SFRPs: A declaration of (Wnt) independence. Nat Cell Biol 11: 13, 2009.
42. Olsen KC, Epa AP, Kulkarni AA, Kottmann RM, McCarthy CE, Johnson GV, Thatcher TH, Phipps RP, Sime PJ. Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules. Am J Respir Cell Mol Biol 50: 737–747, 2014.
43. Roubille C, Brunel AS, Gahide G, Vernhet Kovacsik H, Le Quellec A. Cytomegalovirus (CMV) and acute myocarditis in an immunocompetent patient. Intern Med 49: 131–133, 2010.
44. Ryoke T, Gu Y, Mao L, Hongo M, Clark RG, Peterson KL, Ross J Jr. Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. Circulation 100: 1734–1743, 1999.
45. Satoh W, Gotoh T, Tsunematsu Y, Aizawa S, Shimono A. Sfrp1 and Sfrp2 regulate anteroposterior axis elongation and somite segmentation during mouse embryogenesis. Development 133: 989–999, 2006.
46. Satou Y, Al-Shawafi HA, Sultana S, Makita S, Sohda M, Oda K. Disulfide bonds are critical for tissue-nonspecific alkaline phosphatase function revealed by analysis of mutant proteins bearing a C(201)-Y or C(489)-S substitution associated with severe hypophosphatasia. Biochim Biophys Acta 1822: 581–588, 2012.
47. Schuetze KB, McKinsey TA. TNAP: A new player in cardiac fibrosis? Focus on “Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts.” Am J Physiol Cell Physiol (June 24, 2015). doi: 10.1152/ajpcell.00167.2015.
48. Schumann H, Holtz J, Zerkowski HR, Hatzfeld M. Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression. Cardiovasc Res 45: 720–728, 2000.
49. Shabbir A, Zisa D, Lin H, Mastri M, Roloff G, Suzuki G, Lee T. Activation of host tissue trophic factors through JAK/STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair. Am J Physiol Heart Circ Physiol 299: H1428–H1438, 2010.
50. Shabbir A, Zisa D, Suzuki G, Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 296: H1888–H1897, 2009.
51. Topaz O. Myocardial calcifications in infants with congenital heart disease. Pediatr Cardiol 7: 75–78, 1986.
52. von Marschall Z, Fisher LW. Secreted Frizzled-related protein-2 (sFRP2) augments canonical Wnt3a-induced signaling. Biochem Biophys Res Commun 400: 299–304, 2010.
53. Wang X, Gerdes AM. Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: III. Intercalated disc remodeling. J Mol Cell Cardiol 31: 333–343, 1999.
54. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast- mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10: 15–26, 2013.
55. Whyte MP. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann NY Acad Sci 1192: 190–200, 2010.
56. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 18: 1028–1040, 2012.
57. Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, He Y, Whitworth GE, Stubbs KA, McEachern EJ, Davies GJ, Vocadlo DJ. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4: 483–490, 2008.
58. Zisa D, Shabbir A, Mastri M, Suzuki G, Lee T. Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells. Am J Physiol Regul Integr Comp Physiol 297: R1503–R1515, 2009.
59. Zisa D, Shabbir A, Mastri M, Taylor T, Aleksic I, McDaniel M, Suzuki G, Lee T. Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair. Am J Physiol Heart Circ Physiol 301: H2422–H2432, 2011.